Biovitrum, a developer of protein-based medicines, and Karolinska Development, a Swedish investment company, have signed an agreement to establish a jointly owned project company. This company will receive
Sopherion Therapeutics, a developer and marketer of anticancer therapies, has completed enrollment in its pivotal Phase III study of nonpegylated liposomal doxorubicin, or Myocet, in metastatic HER-2-overexpressing breast
Cedarburg Pharmaceuticals, a provider of active pharmaceutical ingredients and key intermediates for the pharmaceutical and biopharmaceutical industries, has acquired InB: Hauser Pharmaceutical Services, a contract development manufacturing organization.
Epix Pharmaceuticals, a biopharmaceutical company, has received a new patent from the US Patent and Trademark Office. The granted claims of this patent are directed to the highly
Phalanx Biotech Group will integrate the Resolver system into its high throughput OneArray service center for customers who seek whole-genome gene expression and miRNA profiling services. The software
Mr Stein’s resignation is not due to any disagreement with the company on any matter related to its operations, policies, and practices, the company said. David Hirsch, the
Mukesh Jain, chairman of Jainsons, said: “This is a very innovative and exciting technological breakthrough for breast cancer detection. This can revolutionize the breast cancer industry and has
Cephalon, a biopharmaceutical company, has reported positive results from a Phase II clinical trial of Nuvigil tablets as adjunctive therapy for treating major depressive disorder in adults with
In this role, Dr Gardiner will be responsible for leading and coordinating investigator-initiated research projects, clinical publications and presentations and overall medical support for the clinical collaborators and
This X-Suit NIR stent will launch in Europe and parts of Asia on March 27, 2009 followed by the US on April 24, 2009. In Japan and other
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.